Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05391893 · ClinicalTrials.gov registry record · Phase 4
Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation
A Phase 4 study of Atrial Fibrillation and Atrial Flutter, sponsored by Corewell Health South.
- Completed
- Registry status
- Phase 4
- Development phase
- 444
- Enrollment target
- 1
- Study location
NCT05391893: Completed Phase 4 study of Atrial Fibrillation and Atrial Flutter, sponsored by Corewell Health South.
NCT05391893 is a Phase 4 study of Atrial Fibrillation and Atrial Flutter that has completed, run by Corewell Health South. The registered enrollment target is 444 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05391893, a Phase 4 study of Atrial Fibrillation and Atrial Flutter, has completed, sponsored by Corewell Health South.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 444 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.
Primary Outcome
This will compare rates of patients admitted between the protocol group and patients treated traditionally
Conditions Studied
Interventions
- DRUG Oral
- DRUG Intravenous drug
Study Locations (1)
Michigan
- Matthew Hysell - Saint Joseph
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2020-06-19 |
| Est. Completion | 2023-04-01 |
| Phase | Phase 4 |
What the finished NCT05391893 record still lists
NCT05391893 is an interventional study that assigns participants to a tested intervention. The registered 444 participants enrollment target is mid-sized for trials with a published cap, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Oral is the first listed.
NCT05391893 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT05391893 about?
NCT05391893 is a clinical study titled "Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation". The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effectiv...
What is the current status of trial NCT05391893?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 444 participants. The study started on 2020-06-19. Estimated completion is 2023-04-01.
What conditions does trial NCT05391893 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Atrial Flutter.
What interventions are being tested in trial NCT05391893?
The interventions under investigation include: Oral (DRUG), Intravenous drug (DRUG).
Who is sponsoring clinical trial NCT05391893?
This trial is sponsored by Corewell Health South, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05391893 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05391893's enrollment target sits among peer trials
444 65th of 202 higher than 138 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
ACTIVE NOT RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06348394 · 444 participants · NA
Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion
- NCT06700343 · 444 participants · Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
- NCT01280994 · 445 participants · Phase 2
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
- NCT03504800 · 445 participants
OCT in Diagnosis of Irregular Corneas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI